Literature DB >> 19259293

Neuroendocrine tumors: is there a standard treatment?

Matthew H Kulke1.   

Abstract

Entities:  

Year:  2008        PMID： 19259293      PMCID： PMC2633073     

Source DB:  PubMed          Journal:  Gastrointest Cancer Res        ISSN： 1934-7820


× No keyword cloud information.
  15 in total

1.  Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.

Authors:  Christian Waldherr; Miklos Pless; Helmut R Maecke; Tilmann Schumacher; Armin Crazzolara; Egbert U Nitzsche; Andreas Haldemann; Jan Mueller-Brand
Journal:  J Nucl Med       Date:  2002-05       Impact factor: 10.057

2.  Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors.

Authors:  Matthew H Kulke; Keith Stuart; Peter C Enzinger; David P Ryan; Jeffrey W Clark; Alona Muzikansky; Michele Vincitore; Ann Michelini; Charles S Fuchs
Journal:  J Clin Oncol       Date:  2006-01-20       Impact factor: 44.544

3.  High-dose indium 111In pentetreotide radiotherapy for metastatic atypical carcinoid tumor.

Authors:  M O Meyers; L B Anthony; K E McCarthy; G Drouant; T J Maloney; G D Espanan; E A Woltering
Journal:  South Med J       Date:  2000-08       Impact factor: 0.954

4.  Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies.

Authors:  Lowell B Anthony; Eugene A Woltering; Gregory D Espenan; Michele D Cronin; Tom J Maloney; Kevin E McCarthy
Journal:  Semin Nucl Med       Date:  2002-04       Impact factor: 4.446

5.  Long-term efficacy of high-activity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors.

Authors:  John R Buscombe; Martyn E Caplin; Andrew J W Hilson
Journal:  J Nucl Med       Date:  2003-01       Impact factor: 10.057

6.  90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies.

Authors:  G Paganelli; L Bodei; D Handkiewicz Junak; P Rocca; S Papi; M Lopera Sierra; M Gatti; M Chinol; M Bartolomei; M Fiorenza; C Grana
Journal:  Biopolymers       Date:  2002       Impact factor: 2.505

7.  Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors.

Authors:  Sara Ekeblad; Anders Sundin; Eva Tiensuu Janson; Staffan Welin; Dan Granberg; Henrik Kindmark; Kristina Dunder; Gordana Kozlovacki; Håkan Orlefors; Mattias Sigurd; Kjell Oberg; Barbro Eriksson; Britt Skogseid
Journal:  Clin Cancer Res       Date:  2007-05-15       Impact factor: 12.531

8.  Biology and treatment of metastatic gastrointestinal neuroendocrine tumors.

Authors:  Jonathan R Strosberg; Aejaz Nasir; Pamela Hodul; Larry Kvols
Journal:  Gastrointest Cancer Res       Date:  2008-05

9.  A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas.

Authors:  I Duran; J Kortmansky; D Singh; H Hirte; W Kocha; G Goss; L Le; A Oza; T Nicklee; J Ho; D Birle; G R Pond; D Arboine; J Dancey; S Aviel-Ronen; M-S Tsao; D Hedley; L L Siu
Journal:  Br J Cancer       Date:  2006-10-10       Impact factor: 7.640

10.  Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate.

Authors:  D J Kwekkeboom; W H Bakker; B L Kam; J J M Teunissen; P P M Kooij; W W de Herder; R A Feelders; C H J van Eijck; M de Jong; A Srinivasan; J L Erion; E P Krenning
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-01-09       Impact factor: 9.236
View more
  9 in total

1.  Loss of DPC4/SMAD4 expression in primary gastrointestinal neuroendocrine tumors is associated with cancer-related death after resection.

Authors:  Christina L Roland; Lee F Starker; Y Kang; Deyali Chatterjee; Jeannelyn Estrella; Asif Rashid; Matthew H Katz; Thomas A Aloia; Jeffrey E Lee; Arvind Dasari; James C Yao; Jason B Fleming
Journal:  Surgery       Date:  2016-11-03       Impact factor: 3.982

2.  The LARO-MEN1 study: a longitudinal clinical experience with octreotide Long-Acting Release in patients with Multiple Endocrine Neoplasia type 1 Syndrome.

Authors:  Federica Cioppi; Luisella Cianferotti; Laura Masi; Francesca Giusti; Maria Luisa Brandi
Journal:  Clin Cases Miner Bone Metab       Date:  2017-10-25

Review 3.  Multimodal management of neuroendocrine liver metastases.

Authors:  Andrea Frilling; Georgios C Sotiropoulos; Jun Li; Oskar Kornasiewicz; Ursula Plöckinger
Journal:  HPB (Oxford)       Date:  2010-08       Impact factor: 3.647

Review 4.  The role of antiangiogenesis therapy: bevacizumab and beyond.

Authors:  Hernán Cortés-Funes
Journal:  Clin Transl Oncol       Date:  2009-06       Impact factor: 3.405

5.  Kaposi's Sarcoma-Associated Herpesvirus Infection Induces the Expression of Neuroendocrine Genes in Endothelial Cells.

Authors:  Mohanan Valiya Veettil; Gayathri Krishna; Arunava Roy; Anandita Ghosh; Dipanjan Dutta; Binod Kumar; Sayan Chakraborty; Thoppil Raveendran Anju; Neelam Sharma-Walia; Bala Chandran
Journal:  J Virol       Date:  2020-03-31       Impact factor: 5.103

6.  The PARP inhibitor ABT-888 potentiates dacarbazine-induced cell death in carcinoids.

Authors:  Y Somnay; S Lubner; H Gill; J B Matsumura; H Chen
Journal:  Cancer Gene Ther       Date:  2016-09-16       Impact factor: 5.987

7.  The impact of pathologic differentiation (well/poorly) and the degree of Ki-67 index in patients with metastatic WHO grade 3 GEP-NECs.

Authors:  Hee Kyung Kim; Sang Yun Ha; Jeeyun Lee; Se Hoon Park; Joon Oh Park; Ho Yeong Lim; Won Ki Kang; Young Suk Park; Seung Tae Kim
Journal:  Oncotarget       Date:  2017-05-25

Review 8.  Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors.

Authors:  Paola Di Giacinto; Francesca Rota; Laura Rizza; Davide Campana; Andrea Isidori; Andrea Lania; Andrea Lenzi; Paolo Zuppi; Roberto Baldelli
Journal:  Int J Endocrinol       Date:  2018-07-02       Impact factor: 3.257

9.  Targeted radionuclide therapy.

Authors:  Devrim Ersahin; Indukala Doddamane; David Cheng
Journal:  Cancers (Basel)       Date:  2011-10-11       Impact factor: 6.639
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.